AARD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities claims against Aardvark Therapeutics and says a federal securities class action has been filed against the company. Investors who purchased or acquired specified Aardvark securities from the February 13, 2025 IPO through May 14, 2026 are reminded that October 13, 2026 is the deadline to seek lead-plaintiff status.

Analysis

This is a procedural litigation notice, not evidence that the allegations have been tested or that AARD faces an imminent judgment. The lead-plaintiff deadline may create a brief headline/volatility window, but by itself provides little basis to estimate liability, damages, or a change in the company’s operating outlook. The underlying complaint, alleged corrective disclosure, and any company response are the decision-relevant information and are not supplied here.

Near term (days): expect possible event-driven trading and wider volatility around the deadline; do not infer that the deadline establishes the merits. Over 1–3 months, monitor court filings for the specific alleged misstatements, claimed loss period, and any motion to dismiss. A sustained legal overhang could weigh on sentiment or access to capital if it coincides with adverse company-specific developments, but that interaction is conditional—not established by this notice. Over 6–18 months, the economic impact depends on case survival, potential damages and insurance coverage, and any operational or financing consequences; none can be quantified from the available information.

Contrarian read: the notice may draw attention to downside while overstating the informational value of a routine plaintiff-recruitment announcement. Conversely, treating it as immaterial before reviewing the complaint risks missing a potentially important disclosure issue. No defensible directional edge is established yet.

Key Decisions for Investors

• No fresh outright short or options position on this notice alone: the procedural catalyst is limited, while short-squeeze and event-volatility risks are unquantified.
• For existing AARD exposure, review the complaint and company filings before changing risk; specifically verify the alleged corrective disclosure, securities and dates covered, claimed damages, and any company response.
• Set an alert for court docket developments after the October 13, 2026 lead-plaintiff deadline. Reassess if the complaint survives an early dismissal challenge or if filings identify material undisclosed information; the thesis weakens if claims are dismissed or materially narrowed.
• Track AARD-specific operating and financing disclosures alongside the litigation. Escalate only if the legal overhang is accompanied by a guidance change, deterioration in cash runway, or another independently verifiable adverse development.